drugset / Trial / NCT02628860

Efficacy of Ferric Carboxymaltose (Ferinject®) in Anemic Patients Anticipating Pancreatoduodenectomy

NCT02628860

NaSingle-groupOpen-labelTreatment

Summary

This phase II study is to evaluate the safety and efficacy of Ferinject® in reducing perioperative transfusion in iron deficiency anemia patients anticipating pancreatoduodenectomy.

Timeline

Start
2014-01
Primary completion
2020-04-27
Completion
2020-04-27

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Ferric carboxymaltose Other / unclassified 500 mg Intravenous
Subject Ferric carboxymaltose Other / unclassified 1000 mg Intravenous